ELTP · Elite Pharmaceuticals Inc /Nv/ · Executive Compensation
$0.27
+0.01 (+4.21%)
At close · Oct 8
Return incl. dividend (before tax)
Going-concern doubt
— cleared Aug 13, 2026
The latest filing no longer states the doubt (first flagged Jun 29, 2026).
View the 10-Q filed Aug 13, 2026Market Cap
$274.67M
Shares
1.08B
Volume · Oct 8
829.09K
Avg daily vol (3M)
765.79K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Carter J. Ward | secretary | Appointed | 2023-09-07 |
| Carter J. Ward | chief financial officer | Appointed | 2023-09-07 |
| Mark Pellegrino | Chief Financial Officer | Appointed | 2023-05-03 |
| Robert Chen | Chief Financial Officer, Treasurer and Secretary | Resigned | 2023-02-28 |
| Kirko Kirkov | Chief Commercial Officer | Appointed | 2022-09-07 |